(April 14, 2017, 9:59 AM EDT) -- BOSTON — Lead plaintiffs in a securities class action lawsuit against a pharmaceutical company and its CEO failed to plead allegations giving rise to a strong inference of scienter in making their federal securities law claims, a First Circuit U.S. Court of Appeals panel ruled April 7 in affirming a lower court’s dismissal ruling (Terry Brennan, et al. v. Zafgen Inc., et al., No. 16-2057, 1st Cir., 2017 U.S. App. LEXIS 6052)....